Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky

Sionna Therapeutics Shares Lost Roughly 90% of Their Value After Phase 2a PreciSION CF Trial of SION-719 Failed to Achieve Its Key Sweat Chloride Endpoint. NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Sionna Therapeutics (NASDAQ: SION) shares collapsed approximately 92% after the Company...